ZELTIQ Aesthetics Announces First Quarter 2013 Financial Results
April 25 2013 - 4:01PM
REITERATES 2013 GUIDANCE
- Total revenue of $20.0 million, up 15% compared to
$17.4 million in Q1 2012
- 112 systems shipped, compared to 130 systems in Q1
2012, bringing total system installed base to 1,595
systems
- 77,559 cycles shipped, up 21% from Q1 2012 and up 3%
sequentially from Q4 2012
ZELTIQ Aesthetics, Inc., (Nasdaq:ZLTQ) a medical technology company
focused on developing and commercializing products utilizing its
proprietary controlled-cooling technology platform, today announced
financial results for the first quarter 2013.
"We are pleased with our financial results particularly given
the changes we recently implemented," said Mark Foley, President
and Chief Executive Officer. "The adjustments we have made to our
strategy and sales force structure combined with an increased focus
on training are beginning to provide positive momentum for us in
the marketplace. We continue to believe that our bifurcated sales
force structure will allow us to more consistently place new
systems into the field which is an important first step in
achieving our full year revenue objectives. We remain encouraged by
the potential growth opportunity in the non-invasive fat reduction
market and continue to believe that we are in the early stages of
its evolution. The entire ZELTIQ organization is excited and
energized about our start to the year."
First Quarter Financial Review
Total net revenue for the first quarter 2013 was $20.0 million,
consisting of $11.1 million of system revenue and $8.9 million of
consumable revenue. This compares to total net revenue of $17.4
million, consisting of $9.0 million of system revenue and $8.4
million of consumable revenue for the first quarter 2012. Fourth
quarter 2012 total net revenue was $18.6 million, consisting of
$9.6 million of system revenue and $9.0 million of consumable
revenue. Cycles shipped increased 21% to 77,559 for the first
quarter 2013, compared to 63,948 for the first quarter 2012, and up
3% sequentially compared to the 75,172 cycles shipped for the
fourth quarter 2012.
Gross profit was $12.6 million, or 63% of revenue, for the first
quarter 2013, compared to gross profit of $11.4 million, or 66% of
revenue, for the first quarter 2012. Fourth quarter 2012 gross
profit was $12.2 million, or 66% of revenue.
Operating expenses for the first quarter 2013 were $20.1
million, compared to $21.7 million for the first quarter 2012 and
$18.7 million for the fourth quarter 2012.
Net loss for the first quarter 2013 was $7.5 million, compared
to $10.3 million for the first quarter 2012 and $6.5 million for
the fourth quarter 2012. Net loss for the first quarter 2013 was
$0.21 per share, compared to a net loss of $0.30 per share for the
first quarter 2012, and a net loss of $0.18 per share for the
fourth quarter 2012. Weighted average diluted shares outstanding
for the first quarter 2013, first quarter 2012, and fourth quarter
2012 was 35.9 million, 34.0 million and 35.8 million,
respectively.
$51.6 million cash & cash equivalents, short-term and
long-term investments as of March 31, 2013 compared to $58.6
million as of December 31, 2012.
2013 Financial Guidance
ZELTIQ is reiterating its previously stated financial guidance
for the full year 2013, provided on its fourth quarter and full
year 2012 earnings conference call:
- Revenue growth of approximately 10%
- Consumable revenue between 45% to 50% of total revenue
- Gross margin of approximately 66%
- Operating expenses between 97% to 100% of total revenue
- Weighted average basic shares of common stock outstanding of
approximately 36 million
Conference Call
ZELTIQ will hold a conference call on Thursday, April 25, 2013,
at 5:00 p.m. ET to discuss the results. The dial-in numbers are
(877) 280-7291 for domestic callers and (707) 287-9361 for
international callers. A live webcast of the conference call will
be available online from the investor relations page of the
Company's corporate website at www.coolsculpting.com.
After the live webcast, the call will remain available on
ZELTIQ's website, www.coolsculpting.com, until ZELTIQ releases its
second quarter 2013 financial results. In addition, a telephonic
replay of the call will be available until May 2, 2013. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404)
537-3406 for international callers. Please use the replay
conference ID number 35973236.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ's first commercial
product, the CoolSculpting System, is designed to selectively
reduce stubborn fat that may not respond to diet or exercise.
CoolSculpting is based on the scientific principle that fat cells
are more sensitive to cold than the overlying skin and surrounding
tissues. It utilizes patented technology of precisely controlled
cooling to reduce the temperature of fat cells in the treated area,
which is intended to cause fat cell elimination through a natural
biological process known as apoptosis. ZELTIQ developed
CoolSculpting to safely, noticeably, and measurably reduce the fat
layer.
Forward-Looking Statements
The statements made in this press release regarding the benefits
ZELTIQ expects as a result of it having bifurcated its sales force,
as set forth in Mr. Foley's quote, and the information under the
caption "Full Year 2013 Financial Guidance," are forward-looking
statements. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond ZELTIQ's control and that could materially affect the
company's actual business operations and financial performance and
condition. Factors that could materially affect ZELTIQ's business
operations and financial performance and condition include, but are
not limited to: the recent additions to the commercial sales team
may require more time than ZELTIQ expects to integrate these
employees into the company; less than anticipated growth in the
number of physicians electing to purchase CoolSculpting Systems;
patient demand for CoolSculpting procedures may be lower than
ZELTIQ expects; product or procedure announcements by competitors
may decrease demand for CoolSculpting procedures; ZELTIQ may
incorrectly estimate or control its future expenditures; ZELTIQ's
sales and marketing plans may fail to increase sales as ZELTIQ
expects; as well as those other risks and uncertainties set forth
in ZELTIQ's Annual Report on Form 10-K for the fiscal year ended
December 31, 2012, filed with the SEC on March 13, 2013. These
forward-looking statements speak only as of the date of this press
release. ZELTIQ expressly disclaims any obligation to update
information contained in these forward-looking statements whether
as a result of new information, future events or otherwise.
|
|
|
ZELTIQ Aesthetics,
Inc. |
Condensed Consolidated
Statements of Operations |
(Unaudited) |
(In thousands, except
share and per share data) |
|
|
|
|
Three Months
Ended |
|
March
31, |
|
2013 |
2012 |
Revenue |
$ 19,982 |
$ 17,404 |
Cost of revenue |
7,348 |
5,993 |
Gross profit |
12,634 |
11,411 |
Operating expenses: |
|
|
Research and development |
3,749 |
3,398 |
Sales and marketing |
12,542 |
14,497 |
General and administrative |
3,808 |
3,853 |
Total operating
expenses |
20,099 |
21,748 |
Loss from operations |
(7,465) |
(10,337) |
Interest income, net |
24 |
29 |
Other expense, net |
(34) |
(17) |
Loss before provision for income taxes |
(7,475) |
(10,325) |
Provision for income taxes |
7 |
20 |
Net loss |
$ (7,482) |
$ (10,345) |
Net loss per share, basic and diluted |
$ (0.21) |
$ (0.30) |
Weighted average shares of common stock
outstanding used in computing net loss per share, basic and
diluted |
35,890,084 |
34,010,432 |
|
|
|
|
|
|
ZELTIQ Aesthetics,
Inc. |
Condensed Consolidated
Balance Sheets |
(Unaudited) |
(In
thousands) |
|
|
|
|
March 31, 2013 |
December 31,
2012 |
ASSETS |
|
|
CURRENT ASSETS: |
|
|
Cash and cash equivalents |
$ 16,846 |
$ 22,876 |
Short-term investments |
25,359 |
22,563 |
Accounts receivable, net |
6,008 |
7,133 |
Inventory |
9,505 |
10,871 |
Prepaid expenses and other current
assets |
4,396 |
3,600 |
Total current assets |
62,114 |
67,043 |
Long-term investments |
9,364 |
13,141 |
Restricted cash |
362 |
469 |
Property and equipment, net |
2,149 |
2,336 |
Intangible asset, net |
7,006 |
7,181 |
Other assets |
99 |
99 |
Total assets |
$ 81,094 |
$ 90,269 |
LIABILITIES AND STOCKHOLDERS'
EQUITY |
|
|
CURRENT LIABILITIES: |
|
|
Accounts payable |
$ 2,515 |
$ 4,976 |
Accrued liabilities |
11,038 |
11,076 |
Deferred revenue |
1,042 |
1,401 |
Total current
liabilities |
14,595 |
17,453 |
Other non-current liabilities |
229 |
236 |
Total liabilities |
$ 14,824 |
$ 17,689 |
|
|
|
STOCKHOLDERS' EQUITY: |
|
|
Total stockholders'
equity |
66,270 |
72,580 |
Total liabilities and
stockholders' equity |
$ 81,094 |
$ 90,269 |
CONTACT: Investor Relations:
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
925-474-2500
Nick Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024